PMID- 37865941
OWN - NLM
STAT- MEDLINE
DCOM- 20240105
LR  - 20240312
IS  - 1534-4681 (Electronic)
IS  - 1068-9265 (Linking)
VI  - 31
IP  - 2
DP  - 2024 Feb
TI  - Outcomes Following Cytoreductive Surgery and Hyperthermic Intraoperative 
      Thoraco-Abdominal Chemotherapy with Diaphragm Resection for Peritoneal 
      Carcinomatosis: A Retrospective Cohort Study.
PG  - 1058-1068
LID - 10.1245/s10434-023-14470-8 [doi]
AB  - PURPOSE: We aimed to evaluate the safety and efficacy of hyperthermic 
      intraoperative thoraco-abdominal chemotherapy (HITAC) and cytoreductive surgery 
      (CRS) for peritoneal carcinomatosis (PC) patients who underwent diaphragm 
      resection. METHODS: PC patients who underwent CRS with diaphragm resection were 
      selected from a prospectively established database and were divided into 
      hyperthermic intraperitoneal chemotherapy (HIPEC) and HITAC groups. The 
      clinicopathological characteristics, treatment-related variables, perioperative 
      adverse events (AEs), and survival outcomes were compared between the two groups. 
      RESULTS: Of 1168 CRS + HIPEC/HITACs, 102 patients were enrolled-61 HITAC patients 
      and 41 HIPEC patients. In the HITAC and HIPEC groups, the incidence of grade 
      III-V AEs was 29.5% versus 34.1% (p = 0.621). The pleural progression rates were 
      13.2 versus 18.9% (p = 0.462) and the median overall survival (OS) was 50.5 
      versus 52.7 months (p = 0.958). Median time to progression (TTP) in thoracic 
      disease was not reached. There was no significant difference in perioperative 
      AEs, TTP, and OS for total patients and the completeness of cytoreduction (CC) 
      score subgroups (p > 0.05). Age >/= 60 years (hazard ratio [HR] 4.162, p = 0.026) 
      was an independent risk factor influencing pleural progression, and primary 
      malignant peritoneal mesothelioma (MPM; HR 2.749, p = 0.016) and the presence of 
      two or more serious AEs (SAEs; HR 7.294, p = 0.001) were independent risk factors 
      influencing OS. CONCLUSIONS: HITAC can be performed in carefully selected PC 
      patients who underwent diaphragm resection, with no worsening of the safety 
      profile and a possible benefit for pleural progression. In those patients, age 
      >/= 60 years is associated with a shorter TTP of thoracic disease, while primary 
      MPM and two or more perioperative SAEs are associated with worse OS.
CI  - (c) 2023. Society of Surgical Oncology.
FAU - Liu, Gang
AU  - Liu G
AD  - Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Ji, Zhong-He
AU  - Ji ZH
AD  - Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Li, Xin-Bao
AU  - Li XB
AD  - Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital 
      Medical University, Beijing, China.
FAU - An, Song-Lin
AU  - An SL
AD  - Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Zhang, Yan-Bin
AU  - Zhang YB
AD  - Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Li, Bing
AU  - Li B
AD  - Department of Surgical Oncology, Beijing Tsinghua Changgung Hospital, Tsinghua 
      University, Beijing, China.
FAU - Yu, Yang
AU  - Yu Y
AD  - Department of Surgical Oncology, Beijing Tsinghua Changgung Hospital, Tsinghua 
      University, Beijing, China.
FAU - Zhao, Xin
AU  - Zhao X
AD  - Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Peking 
      University Ninth School of Clinical Medicine, Beijing, China.
FAU - Yang, Rui
AU  - Yang R
AD  - Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Li, Yan
AU  - Li Y
AD  - Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital 
      Medical University, Beijing, China. liyansd2@163.com.
AD  - Department of Surgical Oncology, Beijing Tsinghua Changgung Hospital, Tsinghua 
      University, Beijing, China. liyansd2@163.com.
LA  - eng
PT  - Journal Article
DEP - 20231022
PL  - United States
TA  - Ann Surg Oncol
JT  - Annals of surgical oncology
JID - 9420840
SB  - IM
CIN - Ann Surg Oncol. 2024 Feb;31(2):1069-1070. PMID: 37952219
MH  - Humans
MH  - Middle Aged
MH  - *Peritoneal Neoplasms/pathology
MH  - Combined Modality Therapy
MH  - Cytoreduction Surgical Procedures/adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Retrospective Studies
MH  - Diaphragm/pathology
MH  - Chemotherapy, Cancer, Regional Perfusion
MH  - *Hyperthermia, Induced
MH  - Survival Rate
EDAT- 2023/10/22 18:41
MHDA- 2024/01/05 06:43
CRDT- 2023/10/22 15:14
PHST- 2023/07/28 00:00 [received]
PHST- 2023/10/05 00:00 [accepted]
PHST- 2024/01/05 06:43 [medline]
PHST- 2023/10/22 18:41 [pubmed]
PHST- 2023/10/22 15:14 [entrez]
AID - 10.1245/s10434-023-14470-8 [pii]
AID - 10.1245/s10434-023-14470-8 [doi]
PST - ppublish
SO  - Ann Surg Oncol. 2024 Feb;31(2):1058-1068. doi: 10.1245/s10434-023-14470-8. Epub 
      2023 Oct 22.